In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Concerning your Journavx and OxyContin comment, 60 years ago our federal government for the first time was making its 1965 dimes and quarters with no silver content and mak ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Scientists observe plastic ice, a rare hybrid of solid and liquid, forming under extreme conditions, revealing planetary ...

Texas health officials said Tuesday the state now has 58 confirmed measles cases. What is measles, how do you contract it and ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

In his early 20s, Pope Francis underwent surgery to remove a part of his lung affected by a severe respiratory infection.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and powerful pain relievers. In a pair of clinical trials each ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...